The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PROCEADE PanTumor: A phase 1b/2, multicenter study of precemtabart tocentecan (M9140), an anti-CEACAM5 antibody-drug conjugate (ADC) with exatecan payload, in patients with advanced solid tumors.
 
Zev Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Ipsen; Janssen Oncology; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; Revolution Medicines; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck
 
Benjamin Besse
Honoraria - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); OSE Immunotherapeutics (Inst); Sanofi/Aventis (Inst); SERVIER (Inst)
Consulting or Advisory Role - Abbvie (Inst); beijin avistone (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); CureVac (Inst); Ellipses Pharma (Inst); F. Hoffmann LaRoche (Inst); Foghorn Therapeutics (Inst); Immunocore (Inst); Lilly (Inst); Owkin (Inst); PharmaMar (Inst); Regeneron (Inst); Sanofi/Aventis (Inst)
Research Funding - Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); CureVac (Inst); Daiichi Sankyo Europe GmbH (Inst); Enliven Therapeutics (Inst); Genmab (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); OSE Immunotherapeutics (Inst); PharmaMar (Inst); Prelude Therapeutics (Inst); Sanofi (Inst); Takeda (Inst)
 
Athanasios Pallis
Employment - Merck KGaaA
Stock and Other Ownership Interests - Abbvie; AstraZeneca; GlaxoSmithKline; Pfizer
 
Christina Habermehl
Employment - Merck KGaA
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; BeiGene; Chugai Pharma; Daiichi Sankyo/UCB Japan; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Beigene (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)